Recent developments
Regulatory and administration
European and US regulators advanced oncology and neurology options, including the European Commission approval of IMAAVY (nipocalimab) for gMG and FDA approval of KEYTRUDA and Padcev for muscle‑invasive bladder cancer, alongside subcutaneous KEYTRUDA authorization across the EU and Lunsumio subcutaneous approval in the EU.
Diagnostics progressed with Roche's point‑of‑care test for Bordetella infections gaining FDA and CE approval, while infectious disease saw Merck’s positive Phase 3 results for DOR/ISL.
Metabolic therapies and access
Anti‑obesity and metabolic pipelines moved forward with Novo Nordisk’s sNDA for semaglutide 7.2 mg and phase 2 results for amycretin in type 2 diabetes.
Access dynamics shifted as Lilly announced a price reduction for Zepbound single‑dose vials, while the evoke and evoke+ phase 3 trials of oral semaglutide showed no significant impact on Alzheimer’s progression.
Ecosystem and capacity expansion
Capacity and ecosystem expansion featured WuXi Biologics' CRDMO expansion to Qatar and a new Lilly Gateway Labs site in Philadelphia to support early‑stage biotech.
Supply chain and packaging capabilities broadened via Aptar's acquisition of Sommaplast for oral dosing packaging solutions, while leadership shifts included Genmab's appointment of Séverine Lemoine as France GM.
Manufacturing and pipeline moves
Decarbonisation initiatives reached pharma manufacturing through the power purchase agreement between Iberdrola and Bayer and a heat purchase agreement to electrify Bayer’s La Felguera site.
Pipeline diversification continued with Toray’s exclusive worldwide license for TRK‑750 to Sanodyne and Fenestrated TREO IDE study launch in the US.